Trial Profile
A Randomized, Subject- and Investigator-Blind, Placebo and Active-Controlled Study to Assess the Abuse Potential of Lasmiditan
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Jul 2020
Price :
$35
*
At a glance
- Drugs Lasmiditan (Primary) ; Alprazolam
- Indications Migraine
- Focus Pharmacodynamics
- Sponsors Eli Lilly and Company
- 26 May 2020 Results assessing pharmacokinetics, safety and tolerability of lasmiditan in elderly and young healthy subjects from two clinical studies: NCT03286218 and NCT03310411 presented at the 6th Congress of the European Academy of Neurology
- 20 Nov 2019 Results published in the Journal of Clinical Pharmacology
- 11 Dec 2017 Status changed from recruiting to completed.